UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 上皮性卵巣癌、卵管癌、または原発性腹膜癌患者の付属器腫瘤の評価のための血清バイオマーカーserum biomarkers for evaluation of an adnexal mass for epithelial carcinoma of the ovary fallopian tube or peritoneum [show details]
…biomarkers for epithelial ovarian cancer (EOC). Use of cancer antigen 125 (CA 125) as a biomarker for EOC was first described in 1983 . CA 125 is currently the most widely used biomarker for EOC, and it is approved …
2. 卵巣癌のスクリーニングscreening for ovarian cancer [show details]
… However, the specificity of CA 125 is limited. CA 125 levels are elevated in approximately 1 percent of healthy women and fluctuate during the menstrual cycle . CA 125 is also increased in a variety of …
3. 卵巣上皮癌、卵管癌、腹膜癌の生存者への対応approach to survivors of epithelial ovarian fallopian tubal or peritoneal carcinoma [show details]
…CA 125 or new or worsening symptom). For women with EOC, serial measurement of CA 125 is a component of follow-up and there are no guidelines to inform the appropriate time point at which CA 125 surveillance …
4. 上皮性卵巣癌、卵管癌、および腹膜癌の概要overview of epithelial carcinoma of the ovary fallopian tube and peritoneum [show details]
…longitudinally by CA 125 may help identify patients for surgical treatment at recurrence and thereby increase the likelihood of an optimal cytoreduction. However, there is no clear impact of serial CA 125 measurements …
5. 子宮癌肉腫の臨床的特徴、診断、病期分類、および治療clinical features diagnosis staging and treatment of uterine carcinosarcoma [show details]
…CA-125 may signify more advanced disease . In a retrospective study of 54 patients, CA-125 value ≥30 U/mL was significantly associated with higher disease stage (62 versus 38 percent with a CA-125 <30 …

English Journal

Clinical Evaluation of Tumor Markers for Diagnosis in Patients with Non-small Cell Lung Cancer in China.

Ma L, Xie XW, Wang HY, Ma LY, Wen ZG.
Asian Pacific journal of cancer prevention : APJCP. 2015 ;16(12)4891-4.
To evaluate the value of combined detection of serum carcinoembryonic antigen (CEA), cytokeratin 19 fragment (CYFRA21-1), and carbohydrateantigen 125 (CA125) for the clinical diagnosis of non- small cell lung cancer (NSCLC). Serum CEA, CYFRA21-1 and CA125 were assessed in 140 patients with NSCLC, 90
PMID 26163610